In keeping with the proposal that hsa_circ_100053 might be a potential biomarker in CML, higher expression of hsa_circ_100053 was associated with advanced clinical stage, BCR/ABL1 mutational status and resistance to Imatinib. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.